nodes	percent_of_prediction	percent_of_DWPC	metapath
Loratadine—HRH1—Histamine receptors—HRH3—attention deficit hyperactivity disorder	0.138	0.138	CbGpPWpGaD
Loratadine—HRH1—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.0376	0.0376	CbGpPWpGaD
Loratadine—HRH1—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.0369	0.0369	CbGpPWpGaD
Loratadine—HRH1—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.0316	0.0316	CbGpPWpGaD
Loratadine—HRH1—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.031	0.031	CbGpPWpGaD
Loratadine—HRH1—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.0223	0.0223	CbGpPWpGaD
Loratadine—HRH1—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0215	0.0215	CbGpPWpGaD
Loratadine—HRH1—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.0208	0.0208	CbGpPWpGaD
Loratadine—HRH1—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.0201	0.0201	CbGpPWpGaD
Loratadine—HRH1—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.0198	0.0198	CbGpPWpGaD
Loratadine—HRH1—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.0195	0.0195	CbGpPWpGaD
Loratadine—HRH1—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.0188	0.0188	CbGpPWpGaD
Loratadine—HRH1—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.0182	0.0182	CbGpPWpGaD
Loratadine—HRH1—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.0175	0.0175	CbGpPWpGaD
Loratadine—KCNH2—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.017	0.017	CbGpPWpGaD
Loratadine—HRH1—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.0169	0.0169	CbGpPWpGaD
Loratadine—HRH1—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.0166	0.0166	CbGpPWpGaD
Loratadine—HRH1—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.0164	0.0164	CbGpPWpGaD
Loratadine—HRH1—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.0153	0.0153	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.0139	0.0139	CbGpPWpGaD
Loratadine—HRH1—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.0127	0.0127	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.0119	0.0119	CbGpPWpGaD
Loratadine—CYP2C19—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.0112	0.0112	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.0111	0.0111	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.0111	0.0111	CbGpPWpGaD
Loratadine—HRH1—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.0107	0.0107	CbGpPWpGaD
Loratadine—CYP2D6—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.0103	0.0103	CbGpPWpGaD
Loratadine—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00993	0.00993	CbGpPWpGaD
Loratadine—KCNH2—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00871	0.00871	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00834	0.00834	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00805	0.00805	CbGpPWpGaD
Loratadine—KCNH2—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00749	0.00749	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00726	0.00726	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00712	0.00712	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00707	0.00707	CbGpPWpGaD
Loratadine—KCNH2—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00696	0.00696	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.0068	0.0068	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00622	0.00622	CbGpPWpGaD
Loratadine—KCNH2—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00621	0.00621	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.0061	0.0061	CbGpPWpGaD
Loratadine—CYP2C8—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00568	0.00568	CbGpPWpGaD
Loratadine—KCNH2—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00528	0.00528	CbGpPWpGaD
Loratadine—KCNH2—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00524	0.00524	CbGpPWpGaD
Loratadine—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00507	0.00507	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00493	0.00493	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00474	0.00474	CbGpPWpGaD
Loratadine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00467	0.00467	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00464	0.00464	CbGpPWpGaD
Loratadine—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00463	0.00463	CbGpPWpGaD
Loratadine—HRH1—IL-4 Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.00455	0.00455	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00431	0.00431	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00423	0.00423	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00401	0.00401	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00399	0.00399	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00388	0.00388	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00382	0.00382	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00377	0.00377	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00369	0.00369	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00363	0.00363	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.0036	0.0036	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00351	0.00351	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00343	0.00343	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00333	0.00333	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00327	0.00327	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00327	0.00327	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00323	0.00323	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00322	0.00322	CbGpPWpGaD
Loratadine—HRH1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00318	0.00318	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00312	0.00312	CbGpPWpGaD
Loratadine—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00305	0.00305	CbGpPWpGaD
Loratadine—CYP2C8—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00304	0.00304	CbGpPWpGaD
Loratadine—CYP2C8—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00302	0.00302	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00301	0.00301	CbGpPWpGaD
Loratadine—CYP2C8—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.003	0.003	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00285	0.00285	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00281	0.00281	CbGpPWpGaD
Loratadine—CYP2C19—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00271	0.00271	CbGpPWpGaD
Loratadine—CYP2C19—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00269	0.00269	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00268	0.00268	CbGpPWpGaD
Loratadine—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00268	0.00268	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00262	0.00262	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00262	0.00262	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00253	0.00253	CbGpPWpGaD
Loratadine—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.0025	0.0025	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00249	0.00249	CbGpPWpGaD
Loratadine—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00248	0.00248	CbGpPWpGaD
Loratadine—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00247	0.00247	CbGpPWpGaD
Loratadine—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00246	0.00246	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00246	0.00246	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00246	0.00246	CbGpPWpGaD
Loratadine—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00246	0.00246	CbGpPWpGaD
Loratadine—ABCB1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.00244	0.00244	CbGpPWpGaD
Loratadine—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00244	0.00244	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00243	0.00243	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00238	0.00238	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00233	0.00233	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00229	0.00229	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00214	0.00214	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00211	0.00211	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00182	0.00182	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00167	0.00167	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00165	0.00165	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00163	0.00163	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00162	0.00162	CbGpPWpGaD
Loratadine—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00161	0.00161	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.0016	0.0016	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00159	0.00159	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00148	0.00148	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00144	0.00144	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00144	0.00144	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00143	0.00143	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00141	0.00141	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00141	0.00141	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00139	0.00139	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00138	0.00138	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00134	0.00134	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.0013	0.0013	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00129	0.00129	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00128	0.00128	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00126	0.00126	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00124	0.00124	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00118	0.00118	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.00114	0.00114	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00111	0.00111	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00108	0.00108	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00104	0.00104	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00102	0.00102	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00101	0.00101	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000976	0.000976	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000907	0.000907	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000858	0.000858	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000858	0.000858	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000853	0.000853	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000844	0.000844	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000823	0.000823	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000793	0.000793	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000785	0.000785	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000768	0.000768	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000766	0.000766	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000766	0.000766	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000755	0.000755	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000754	0.000754	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000748	0.000748	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000748	0.000748	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000745	0.000745	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000736	0.000736	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000705	0.000705	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000705	0.000705	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000701	0.000701	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000699	0.000699	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000699	0.000699	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000694	0.000694	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000693	0.000693	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000687	0.000687	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000686	0.000686	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000684	0.000684	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000667	0.000667	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000653	0.000653	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000644	0.000644	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000639	0.000639	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000612	0.000612	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000598	0.000598	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000583	0.000583	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000569	0.000569	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000563	0.000563	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000558	0.000558	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000536	0.000536	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000532	0.000532	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—COMT—attention deficit hyperactivity disorder	0.00052	0.00052	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000516	0.000516	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000501	0.000501	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000486	0.000486	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	0.000464	0.000464	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000461	0.000461	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000461	0.000461	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000461	0.000461	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000453	0.000453	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000453	0.000453	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00045	0.00045	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000447	0.000447	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	0.000427	0.000427	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000424	0.000424	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	0.000423	0.000423	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000421	0.000421	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00042	0.00042	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000408	0.000408	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000368	0.000368	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000351	0.000351	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	0.000279	0.000279	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000277	0.000277	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000258	0.000258	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—EP300—attention deficit hyperactivity disorder	0.000223	0.000223	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	0.000199	0.000199	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000194	0.000194	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	0.000183	0.000183	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	0.000181	0.000181	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	0.00012	0.00012	CbGpPWpGaD
